{
  "docId": "019de070-88e9-71fb-bd5e-9cebc40d3d74",
  "docSlug": "efe3c89f76a7f3b64a2396681cf47d00",
  "documentTitle": "Bausch Health Companies | Investor Conference Presentation Deck | 18 slides",
  "authorId": "bausch-health-companies",
  "authorName": "Bausch Health",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 12,
  "pageCount": 18,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a timeline-like structure for R&D milestones and a list for COVID-19 treatments.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-88e9-71fb-bd5e-9cebc40d3d74/12",
  "deckHref": "/decks/019de070-88e9-71fb-bd5e-9cebc40d3d74",
  "deckJsonHref": "/decks/019de070-88e9-71fb-bd5e-9cebc40d3d74.json",
  "deckAnchorHref": "/decks/019de070-88e9-71fb-bd5e-9cebc40d3d74#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.67,
        "y": 0.0023
      },
      "kind": "callout",
      "text": "NOV03 SEECASE Study Published in The Journal of Cornea and External Disease: Study met primary endpoint, change from baseline of tCFS over control, for both dosing regimens QID and BID (P < 0.001 and P = 0.009).",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5623dc3-785e-465b-a271-46fc2e3553b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.92,
        "x": 0.04,
        "y": 0.0063
      },
      "kind": "list",
      "text": "DEXAVEN (dexamethasone phosphate) new indication; In vitro data for LUMIFY and BESIVANCE; IVEXTERM studies ongoing; VIRAZOLE studies ongoing.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d89c972-1f04-4664-a472-0a958cf02fae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.04,
        "y": 0.0024
      },
      "kind": "list",
      "text": "Initiate Amiselimod S1P2 Modulator Phase 2 trial - 1H21; Readout of topline results for NOV03; Initiate Phase 2 trials for rifaximin; Complete enrollment for Eyenovia Phase 3; Start Phase 3 trial for Risuteganib.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e12f461-78a9-4873-9b43-e65a6649b4c4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.25,
        "y": 0.009
      },
      "kind": "source-note",
      "text": "Footnotes 1-11 detailing clinical study references and licensing agreements.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92f6d590-40f3-4480-a096-4ee3b69e2f81",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.3,
        "x": 0.04,
        "y": 0.005900000000000001
      },
      "kind": "title",
      "text": "COVID Focused Treatments",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "532a336c-402d-4267-ad46-a2b871ca71c8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.0015
      },
      "kind": "title",
      "text": "R&D: Upcoming Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62fe3f5c-a4cf-48a5-8905-e780cfb64aa5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.35,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "Near-term Catalysts",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b327d01e-6ec6-4e8e-aabd-7221a94025dc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 12,
      "from": 10,
      "beatId": "38f53168-8fdc-42a2-83e9-c71841f176fd",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Growth drivers and near-term catalysts are discussed",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "ff4374a6-38a6-43da-8254-e054a1e0fd6c",
      "evidence": "The deck discusses near-term catalysts and growth drivers",
      "position": 2,
      "objective": "What are the quick wins and big bets for growth drivers?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}